Fig. 1From: A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal studyAnnualised costs of patient management and biologic therapy in PsA (overall cohort; Mean, 95% C.I.). TNFi (Tumor Necrosis Factor alpha inhibitors)Back to article page